Fig. 6: The impact of phagocytosis activity of KCs on the effect of AAV gene therapy.
From: Gene therapy prevents onset of mitochondrial cardiomyopathy in neonatal mice with Ndufs6 deficiency
A The relative expression of hNdufs6 mRNA in mice liver of Ndufs6gt/gt, AAV-Neonatal and AAV-Adult groups at 3 months post gene therapy (n = 4). B Relative protein expression of NDUFS6 in mice liver was detected in Ndufs6gt/gt, AAV-Neonatal and AAV-Adult groups by Western blot. The quantification results were calculated following two steps by Image J: 1) gray scale for each sample was normalized to GAPDH (WT-1 = WT gray scale/GAPDH gray scale; Ndufs6gt/gt-1 = Ndufs6gt/gt gray scale/GAPDH gray scale; AAV-Neonatal-1 = AAV-Neonatal gray scale/GAPDH gray scale; AAV-Adult-1 = AAV-Adult gray scale/GAPDH gray scale); 2) then Ndufts6gt/gt-1, AAV-Neonatal-1 and AAV-Adult-1 are expressed as percentage of WT levels. (n = 4). C Immunofluorescence analysis of macrophages displaying DAPI, mF4/80, and Latex beads. The DAPI staining (blue) marks the cell nuclei, mF4/80 staining (red) identifies the macrophage surface receptor, and green fluorescence highlights the phagocytosed Latex beads within the cells. The merged image shows the co-localization of mF4/80 with the Latex beads, confirming the phagocytic activity of mF4/80-positive cells. Scale bar = 20 μm. D Quantification of fluorescence intensity and representative photos of phagocytic activity of KCs in neonatal (PDN1) mice and Adult (3-month-old) mice at 2 h, respectively. Scale bar = 20 μm.
